Viking Therapeutics

Viking Therapeutics

Viking Therapeutics was founded in 2012 and is headquartered in San Diego. CEO Brian Lian has run the biotech since inception, building a development pipeline concentrated entirely on metabolic and endocrine disorders. Therapeutic focus areas span non-alcoholic steatohepatitis (NASH) with VK2809, X-linked adrenoleukodystrophy (X-ALD) with VK0214, and, most prominently, obesity via the dual GLP-1/GIP receptor agonist VK2735. Clinical-stage assets dominate the portfolio, with VK2735’s oral formulation entering Phase 3 development in 2025—the pivotal registrational program targeting the same incretin biology that Eli Lilly and Novo Nordisk have already commercialized at scale. Viking operates with a lean internal team in San Diego and a network of contract research organizations (CROs) running multicenter trials across the United States and Europe. It remains a development-stage company and finances operations through public equity offerings; its Nasdaq listing (ticker: VKTX) provides access to institutional public-market investors rather than a traditional family-office or GP-LP structure. The structural distinction from a conventional family office or venture firm is its status as a publicly traded, single-mission clinical-stage biotech. There is no diversified asset pool, no discretionary allocation to external managers, and no co-investor club. The capital structure is a single corporate balance sheet supporting a focused pipeline, with the board and executive team accountable to public shareholders, not a single family’s wealth.